Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (Iovance), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, has announced the pricing of an underwritten offering of 23,014,000 shares of its common stock at an offering price of US$9.15 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately US$211 million. The offering is expected to close on or about February 22, 2024, subject to customary closing conditions. Latham & Watkins LLP is advising the underwriters in the offering, with a capital markets team led by San Diego partners Matt Bush and Cheston Larson, and counsel Anthony Gostanian, with associates Peter Simon and Sterling Swift.~~